GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Dali Pharmaceutical Co Ltd (SHSE:603963) » Definitions » EV-to-FCF

Dali Pharmaceutical Co (SHSE:603963) EV-to-FCF : -22.74 (As of May. 27, 2024)


View and export this data going back to 2017. Start your Free Trial

What is Dali Pharmaceutical Co EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Dali Pharmaceutical Co's Enterprise Value is ¥739.79 Mil. Dali Pharmaceutical Co's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 was ¥-32.53 Mil. Therefore, Dali Pharmaceutical Co's EV-to-FCF for today is -22.74.

The historical rank and industry rank for Dali Pharmaceutical Co's EV-to-FCF or its related term are showing as below:

SHSE:603963' s EV-to-FCF Range Over the Past 10 Years
Min: -317.29   Med: -60.98   Max: 654.26
Current: -23.89

During the past 12 years, the highest EV-to-FCF of Dali Pharmaceutical Co was 654.26. The lowest was -317.29. And the median was -60.98.

SHSE:603963's EV-to-FCF is ranked worse than
100% of 528 companies
in the Drug Manufacturers industry
Industry Median: 24.695 vs SHSE:603963: -23.89

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-27), Dali Pharmaceutical Co's stock price is ¥4.11. Dali Pharmaceutical Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was ¥-0.104. Therefore, Dali Pharmaceutical Co's PE Ratio for today is At Loss.


Dali Pharmaceutical Co EV-to-FCF Historical Data

The historical data trend for Dali Pharmaceutical Co's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dali Pharmaceutical Co EV-to-FCF Chart

Dali Pharmaceutical Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -110.14 -47.64 -123.10 -79.56 -71.58

Dali Pharmaceutical Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -89.99 -58.74 -48.48 -71.58 -69.27

Competitive Comparison of Dali Pharmaceutical Co's EV-to-FCF

For the Drug Manufacturers - Specialty & Generic subindustry, Dali Pharmaceutical Co's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Dali Pharmaceutical Co's EV-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Dali Pharmaceutical Co's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Dali Pharmaceutical Co's EV-to-FCF falls into.



Dali Pharmaceutical Co EV-to-FCF Calculation

Dali Pharmaceutical Co's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=739.793/-32.532
=-22.74

Dali Pharmaceutical Co's current Enterprise Value is ¥739.79 Mil.
Dali Pharmaceutical Co's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥-32.53 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Dali Pharmaceutical Co  (SHSE:603963) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Dali Pharmaceutical Co's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=4.11/-0.104
=At Loss

Dali Pharmaceutical Co's share price for today is ¥4.11.
Dali Pharmaceutical Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥-0.104.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Dali Pharmaceutical Co EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Dali Pharmaceutical Co's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Dali Pharmaceutical Co (SHSE:603963) Business Description

Traded in Other Exchanges
N/A
Address
No. 118, Huancheng West Road, Yunnan Province, Xiaguan Town, Dali, CHN, 671000
Dali Pharmaceutical Co Ltd operates in the pharmaceutical manufacturing industry. It is engaged in the research and development and production of Chinese and Western medicine injection products. The company's main products are Zhongjing Brand Xingnaojing Injection, Shenmai Injection, Astragalus Injection, Brighten A Injection and Cell Diphosphocholine injection.
Executives
Wu Pei Rong senior management
Yang Jun Xiang Directors, senior managers
Yang Jun Wei Director

Dali Pharmaceutical Co (SHSE:603963) Headlines

No Headlines